Invitae (NYSE: NVTA) has grown revenue over time, but the genetic testing specialist has failed to turn that into profit. Instead, the company burned through more and more cash, prompting it to launch ...

Now is a great time to load up on growth stocks because they may be among the first to benefit in the next bull market. We've already seen some of the biggest ones -- such as Amazon and Apple --take ...

Invitae Corporation (NYSE:NVTA), backed by SoftBank Group (OTC:SFTBY) (OTC:SFTBF), is reportedly on the brink of filing for bankruptcy in the coming weeks. The San Francisco-based medical genetics ...

Invitae, a medical genetic testing company, has filed for Chapter 11 bankruptcy and intends to continue the case without disrupting operations using cash on hand and while seeking to sell its business ...

We recently compiled a list of the 10 Best Stocks to Buy and Hold For 5 Years According to Cathie Wood. In this article, we are going to take a look at where Invitae Corporation (OTC:NVTAQ) stands ...

BURLINGTON, N.C. and SAN FRANCISCO, May 7, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and Invitae, a leading medical genetics company ...

– Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantially All of the Company's ...

Invitae has made progress in its business realignment plan, cutting cash burn by one-half from 2022 to 2023. However, the company still faces significant challenges. Despite efforts, Invitae shares ...

CRISPR Therapeutics may soon generate its first product revenue. Invitae, making progress in its recovery plan, could climb if it meets its goals. One of these stocks may be riskier than the other ...